CN101375859A - Compound composite medicament for preventing and treating iron-deficiency anemia and secondary infection of young stock - Google Patents
Compound composite medicament for preventing and treating iron-deficiency anemia and secondary infection of young stock Download PDFInfo
- Publication number
- CN101375859A CN101375859A CNA200710059425XA CN200710059425A CN101375859A CN 101375859 A CN101375859 A CN 101375859A CN A200710059425X A CNA200710059425X A CN A200710059425XA CN 200710059425 A CN200710059425 A CN 200710059425A CN 101375859 A CN101375859 A CN 101375859A
- Authority
- CN
- China
- Prior art keywords
- secondary infection
- iron
- young stock
- piglet
- deficiency anemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a compound combined drug for prevention and treatment of secondary infection caused by iron deficiency anemia and low immunity of piglets and young animals. The compound combined drug comprises two drugs of iron dextran and tylosin tartrate. The compound combined drug is mainly used for prevention and treatment of bacterial secondary infection caused by iron deficiency anemia and low immunity of the piglets and the young animals. The two drugs are combined for use, when in prevention and treatment of anemia of young animals, the compound combined drug can effectively control piglet diarrhea and other types of bacterial secondary infection caused by poor resistance. The compound combined drug can be prepared into injection, oral liquor and other types of formulations.
Description
Technical field
The invention belongs to field of veterinary, particularly relate to a kind of compound composite medicament that is used to prevent and treat the secondary infection that young stock iron deficiency anemia and newborn young stock hypoimmunity cause.
Background technology
At present, along with the further expansion of intensive culture scale, the ill probability of newborn young stock also day by day rises.Often cause the diseases such as antibacterial secondary infection of young stock iron deficiency anemia, initiation lower for the resistance because of reasons such as feeding and management are slipped up, prevention is untimely.
With piglet anaemia is example, during the piglet birth, the storage capacity of ferrum is extremely low in the body, and piglet is in the pig house on ground if be grown in cement, plank, can not contact with soil, then lost picked-up external source, because the suckling pig growth promoter is rapid, can not satisfy the growth in piglets needs far away simultaneously and only depend on suckling to obtain ferrum to ferrum.Therefore piglet is often because of iron deficiency and then influence the generation of hemoglobin, generation anemia as a result.When anemia takes place in piglet, destroyed the oxidation-reduction process of body, the function of digesting and assimilating of piglet also weakens simultaneously, and this has just more increased the weight of the generation of anemia, and the resistance of ill piglet is very weak, and secondary infection takes place easily.
Equally, be example with the new-born calve, initial several days of nascent calf birth back, immunity is extremely low, often needs to rely on colostrum that basic antibody is provided, to prevent the generation of calf stress and disease.But because the error in the feeding and management is late excessively as the colostrum feeding time, the amount of feeding is very few or feed, and its result causes calf can not obtain maternal antibody and the resistance reduction, the infection of some sensitive organisms of Chang Jifa.
At present, being used for the treatment of the piglet iron deficiency anemia on veterinary clinic is simple oral or intramuscular injection iron preparation, and piglet is not then prevented timely because of anemia causes the secondary infection of initiation lower for the resistance; Equally, for the disease prevention of newborn calf, also because of there not being the excellent prevention medicine often after infecting generation, to treat again, cause prognosis mala at present.
Summary of the invention
Based on above-mentioned situation, the object of the present invention is to provide a kind of compound composite medicament that is used to prevent and treat the secondary infection that young stock iron deficiency anemia and newborn young stock hypoimmunity cause.
The object of the present invention is achieved like this: a kind of compound composite medicament that is used to prevent and treat the secondary infection that young stock iron deficiency anemia and newborn young stock hypoimmunity cause, it is characterized in that: prescription of the present invention is made up of tylosin tartrate and two kinds of medicines of iron dextran.
A kind of compound composite medicament that is used to prevent and treat the secondary infection that young stock iron deficiency anemia and newborn young stock hypoimmunity cause is characterized in that: iron dextran 5-15 part, tylosin tartrate 1-5 part.
Be preferably: 10 parts of iron dextran, 3 parts of tylosin tartrates.
A kind of compound composite medicament that is used to prevent and treat the secondary infection that young stock iron deficiency anemia and newborn young stock hypoimmunity cause, it is characterized in that: the dosage form of described compound medicine can be dosage forms such as injection, oral liquid.
Technology with injection is example, the present invention adopts the industry method in common to make: earlier 10 parts of iron dextran are dropped in 300 liters of waters for injection, stirring and evenly mixing, then 3 parts of tylosin tartrates, 20 parts of solvents and 0.3 portion of antiseptic are added wherein, stir, regulate between pH to 4.5～7.5 with 30%NaOH until the solution clarification, be settled to 1000 liters with water for injection, aseptic filtration, packing, promptly.
Transdermal absorption accelerator described in the technology can be single component or combinations such as ethanol, lauryl alcohol, propylene glycol, ethyl acetate, dimethyl sulfoxine, dimethyl formamide; Antiseptic can be any one in sodium benzoate, benzoic acid, phenol, methyl hydroxybenzoate, the ethyl hydroxybenzoate etc.
Iron dextran is a kind of active iron, the deposit that can participate in synthesizing haemachrome, the regeneration of promotion histaminase and replenish ferrum in the animal body; Tylosin tartrate is effective to gram positive bacteria and some negative bacterium, for oral administration after easily from gastrointestinal absorption, can reach the blood peak concentration of drug in back 1 hour for oral administration to pig, subcutaneous injection also can absorb rapidly.The two is used, and in control young stock anemia, controls the antibacterial secondary infection that causes because of the resistance difference effectively.Wherein, the active iron in the product can discharge ferrum element continuously and enter body, participates in the synthetic of hemoglobin, lasting medicine.Medicine of the present invention can be made multiple dosage forms such as injection, oral liquid, pre-mixing agent,
Curative effect aspect the secondary infection that to be example explanation medicine of the present invention below with the test cause at control young stock iron deficiency anemia and newborn young stock hypoimmunity:
1 materials and methods
1.1 trial drug
Supply the reagent product: dosage form is an injection, and main component is iron dextran and tylosin tartrate, and recommended dose is the 1mL/10kg body weight, the musculi colli injection;
Contrast medicine (A): iron dextran inj, lot number: 20070312, produce by Guangxi animal pharmaceutical factory;
Contrast medicine (B): tylosin injection, lot number: 20070421, certain animal pharmaceutcal corporation, Ltd of effluent north produces.
1.2 experimental animal
120 newborn piglets are provided by pig farm, Ninghe, Tianjin, test in the pig farm and carry out, and 120 piglets are in batches and give birth to, but feeding and management condition must be identical.120 piglets are divided into 6 groups, are respectively: high dose group, middle dosage group, low dose group, contrast medicine group (A), contrast medicine group (B) and blank group.Every group 20 are necessary for a collection of and give birth to.
1.3 test method
The newborn piglet feeding and management method all adopts conventional method, and high dose group is at the medicine of the present invention of birth injection in the 3rd day 2mL/10kg; Middle dosage group is at the medicine of the present invention of birth injection in the 3rd day 1mL/10kg; Low dose group is at the medicine of the present invention of birth injection in the 3rd day 0.5mL/10kg; Contrast medicine group (A) is at the iron dextran inj of birth injection in the 3rd day 1mL/10kg; Contrast medicine group (B) is injected the tylosin injection of 1mL/10kg every day.More than each group remove all medications of contrast medicine group (B) 1 day, contrast medicine group (B) continuous use 3 days, and medication is musculi colli and injects.The blank group is handled without administration.Each laboratory animal body weight of statistics after 7 days, and the piglet that respiratory tract and digestive tract bacterial infection take place in each group concentrated be equally divided into two groups, treat with tylosin injection and medicine of the present invention respectively, add up cured substance rate and effective percentage.
Table 1 test grouping and drug treating
1.4 curative effect determinate standard
Weightening finish: the body weight of every pig during according to on-test and off-test, calculate the gain in weight of every pig, calculate the average growth rate of every group of test pig then in view of the above.The relative weight gain rate is to calculate by the ratio of each medication treatment group with the weightening finish of matched group, and wherein normal healthy controls group pig rate of body weight gain is made as 100%.
Cure: at duration of test piglet transference cure after administration, spirit and appetite are recovered normal person and are belonged to healing, and the ratio that accounts for the morbidity piglet according to the healing piglet calculates cure rate.
Produce effects: in duration of test not complete obiteration but take a favorable turn and be produce effects of piglet symptom after administration, the ratio that accounts for the morbidity piglet according to the produce effects piglet calculates obvious effective rate.
Effectively: be cure rate and obvious effective rate sum.
2 result of the tests
Each organizes the laboratory animal weightening finish and incidence sees Table 2
Table 2 weightening finish and incidence
Therapeutic effect sees Table 3
Table 3 morbidity pig therapeutic effect
By this test as seen: after giving the medicine of the present invention of the high, medium and low dosage of newborn piglet, its rate of body weight gain is much larger than the single test group that gives iron dextran and tylosin, and the probability of generation bacterial infection is almost nil.Wherein high dose group is identical with the effect of middle dosage group.
To cause respiratory tract and digestive tract bacterial infection take place hypoimmunity piglet to be treated owing to iron deficiency after, the effective percentage of medicine of the present invention is 100%, and its curative effect is much larger than utilization tylosin single therapy.
3.2 safety testing
Duration of test centering dosage group is observed: the prothymia of middle dosage group piglet, it is good to search for food.Randomly draw one after the off-test from this group and cut open inspection, its histoorgan there is no unusually, proves that medicine of the present invention is safe.
The specific embodiment
Embodiment 1: 5 parts of iron dextran, 1 part of tylosin tartrate.A kind of compound composite medicament that is used to prevent and treat the secondary infection that young stock iron deficiency anemia and newborn young stock hypoimmunity cause.Prophylactic amount: piglet: every piglet: iron dextran 100-200mg/ day (in ferric iron), tylosin tartrate 30-60mg/ day was used on the 3rd day in the birth back; Calf: every new-born calve: iron dextran 400-800mg/ day (in ferric iron), tylosin tartrate 120-240mg/ day was used on the 3rd day in the birth back; Medicine for treatment amount: iron dextran 100mg, tylosin tartrate 30mg/10kg body weight; Pup, fox: used on the 3rd day birth back, every pup or fox: iron dextran 50-200mg/ day (in ferric iron), tylosin tartrate 15-60mg/ day.
Embodiment 2: 10 parts of iron dextran, 3 parts of tylosin tartrates.A kind of compound composite medicament that is used to prevent and treat the secondary infection that young stock iron deficiency anemia and newborn young stock hypoimmunity cause.Prophylactic amount: piglet: every piglet: iron dextran 100-200mg/ day (in ferric iron), tylosin tartrate 30-60mg/ day was used on the 3rd day in the birth back; Calf: every new-born calve: iron dextran 400-800mg/ day (in ferric iron), tylosin tartrate 120-240mg/ day was used on the 3rd day in the birth back; Medicine for treatment amount: iron dextran 100mg, tylosin tartrate 30mg/10kg body weight; Pup, fox: used on the 3rd day birth back, every pup or fox: iron dextran 50-200mg/ day (in ferric iron), tylosin tartrate 15-60mg/ day.
Embodiment 3: 15 parts of iron dextran, 5 parts of tylosin tartrates.A kind of compound composite medicament that is used to prevent and treat the secondary infection that young stock iron deficiency anemia and newborn young stock hypoimmunity cause.Prophylactic amount: piglet: every piglet: iron dextran 100-200mg/ day (in ferric iron), tylosin tartrate 30-60mg/ day was used on the 3rd day in the birth back; Calf: every new-born calve: iron dextran 400-800mg/ day (in ferric iron), tylosin tartrate 120-240mg/ day was used on the 3rd day in the birth back; Medicine for treatment amount: iron dextran 100mg, tylosin tartrate 30mg/10kg body weight; Pup, fox: used on the 3rd day birth back, every pup or fox: iron dextran 50-200mg/ day (in ferric iron), tylosin tartrate 15-60mg/ day.
Claims (4)
1, a kind of compound composite medicament that is used to prevent and treat the secondary infection that piglet and young stock iron deficiency anemia and newborn young stock hypoimmunity cause, it is characterized in that: prescription of the present invention is made up of tylosin tartrate and two kinds of medicines of iron dextran.
2, a kind of compound composite medicament that is used to prevent and treat the secondary infection that piglet and young stock iron deficiency anemia and newborn young stock hypoimmunity cause according to claim 1, it is characterized in that the present invention writes out a prescription is: iron dextran 5-15 part, tylosin tartrate 1-5 part.
3, a kind of compound composite medicament that is used to prevent and treat the secondary infection that piglet and young stock iron deficiency anemia and newborn young stock hypoimmunity cause according to claim 1, it is characterized in that optimizing prescriptions of the present invention is: 10 parts of iron dextran, 3 parts of tylosin tartrates.
4, a kind of compound composite medicament that is used to prevent and treat the secondary infection that piglet and young stock iron deficiency anemia and newborn young stock hypoimmunity cause according to claim 1, it is characterized in that: the present invention can be made into injection, oral liquor and other types of formulations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200710059425XA CN101375859A (en) | 2007-08-31 | 2007-08-31 | Compound composite medicament for preventing and treating iron-deficiency anemia and secondary infection of young stock |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200710059425XA CN101375859A (en) | 2007-08-31 | 2007-08-31 | Compound composite medicament for preventing and treating iron-deficiency anemia and secondary infection of young stock |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101375859A true CN101375859A (en) | 2009-03-04 |
Family
ID=40419704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200710059425XA Pending CN101375859A (en) | 2007-08-31 | 2007-08-31 | Compound composite medicament for preventing and treating iron-deficiency anemia and secondary infection of young stock |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101375859A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102397288A (en) * | 2010-09-13 | 2012-04-04 | 瑞普（天津）生物药业有限公司 | Iron-dextrin composition without stress reaction |
| CN105079023A (en) * | 2015-08-18 | 2015-11-25 | 河南亚卫动物药业有限公司 | Veterinary compound dextriferron injection and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3491187A (en) * | 1967-02-27 | 1970-01-20 | Diamond Shamrock Corp | Iron salt-antibiotic compositions and use thereof |
-
2007
- 2007-08-31 CN CNA200710059425XA patent/CN101375859A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3491187A (en) * | 1967-02-27 | 1970-01-20 | Diamond Shamrock Corp | Iron salt-antibiotic compositions and use thereof |
Non-Patent Citations (1)
| Title |
|---|
| 严更生: "乳猪饲养技术要点", 《农村养殖技术》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102397288A (en) * | 2010-09-13 | 2012-04-04 | 瑞普（天津）生物药业有限公司 | Iron-dextrin composition without stress reaction |
| CN105079023A (en) * | 2015-08-18 | 2015-11-25 | 河南亚卫动物药业有限公司 | Veterinary compound dextriferron injection and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101375859A (en) | Compound composite medicament for preventing and treating iron-deficiency anemia and secondary infection of young stock | |
| CN115025101B (en) | Lithocholic acid-added medicine for preventing and treating mycotoxin poisoning as well as preparation method and application thereof | |
| CN101468057A (en) | Compound Chinese medicine preparation for treating yellow-white dysentery of piglet | |
| CN101829129B (en) | Veterinary compound gentamycin sulfate injection and preparation method thereof | |
| CN103721240B (en) | Compound formulation for treating bacterial infection of digestive tract of livestock and poultry and preparation method of compound formulation | |
| CN102614294A (en) | Compound amoxicillin suspension injection and preparation method thereof | |
| US3281322A (en) | Methods for controlling and treating renal calculi | |
| CN102755342B (en) | Compound paracetamol injection and preparation method thereof | |
| CN101954084B (en) | Medicinal composition for treating mixed infection in livestock and poultry and preparation method thereof | |
| CN102847160B (en) | Compound quinolone injection for livestock, and preparation method thereof | |
| CN111494509A (en) | A Chinese medicinal injection for treating mastitis of milk cow, and its preparation method | |
| CN108524494A (en) | Application and potassium dehydroandrographolide succinate animal medicament of the potassium dehydroandrographolide succinate in preparing veterinary drug | |
| CN109700757A (en) | A kind of Mesalazine and the compound preparation of paracetamol and application thereof | |
| CN102908610B (en) | Propolis combination used for livestock and preparation method of same | |
| CN1985827B (en) | Compound ciprofloxacin injection for animal and its preparing process | |
| CN102973577B (en) | Compound sodium sulfaquinoxaline composition for treating coccidiosis in young rabbits, and preparation method thereof | |
| CN1232254C (en) | United slow release agent for preventing and treating piglet and rabbit coccidiosis and dysentery and its preparing metod | |
| CN116370488A (en) | Chinese herbal medicine small molecule composition for preventing and treating bacterial gill rot disease of fish | |
| CN1256981C (en) | Medicine for treating piglet white scour and its preparation method | |
| CN115554339A (en) | Pharmaceutical composition for preventing and treating animal diarrhea and preparation method thereof | |
| CN104666307B (en) | Natural drug monomer compound preparation for animals and preparation and application thereof | |
| CN116919946A (en) | Application of quercetin in preparation of medicaments for preventing prostatic cancer | |
| CN105079023A (en) | Veterinary compound dextriferron injection and preparation method thereof | |
| CN101244065A (en) | Combined sustained-release agent for preventing and controlling livestock coccidiosis and bacillary dysentery, and preparation thereof | |
| CN117462527A (en) | Application of gabexate mesylate in preparation of medicines for treating pancreatitis of pets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| ASS | Succession or assignment of patent right |
Owner name: RUIPU ( TIANJIN ) BIOLOGICAL MEDICINE INDUSTRY CO. Free format text: FORMER OWNER: TIANJIN RUIPU BIOLOGICAL CO., LTD., TECHNOLOGY GROUP Effective date: 20090814 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20090814 Address after: Tianjin City, six Dongli Road Development Zone No. 6 Applicant after: Ruip (Tianjin) Biopharmaceutical Co., Ltd. Address before: Tianjin City, six Dongli Road Development Zone No. 6 Applicant before: Tianjin Ringpu Biological Technology Group Co., Ltd. |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20090304 |